About Lonza
Lonza is a company based in Basel (Switzerland) founded in 1897 was acquired by SBI Mutual Fund in February 2024.. Lonza has raised $100 thousand across 6 funding rounds from investors including SBI Mutual Fund, European Union and ALSA Ventures. The company has 18,690 employees as of December 31, 2024. Lonza has completed 11 acquisitions, including Capsugel, InterHealth Nutraceuticals and Lonza. Lonza offers products and services including Integrated Biologics, Advanced Synthesis, and Specialized Modalities. Lonza operates in a competitive market with competitors including Pharmaron, Pfizer, Boehringer Ingelheim, LabConnect and Dotmatics, among others.
- Headquarter Basel, Switzerland
- Employees 18690 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lonza Group Ag
-
Annual Revenue
$7.25 B (USD)-2.13as on Dec 31, 2024
-
Net Profit
$702.02 M (USD)-2.75as on Dec 31, 2024
-
EBITDA
$1.69 B (USD)3.8as on Dec 31, 2024
-
Total Equity Funding
$100 K (USD)
in 6 rounds
-
Latest Funding Round
$100 K (USD), Seed
Nov 25, 2023
-
Investors
SBI Mutual Fund
& 4 more
-
Employee Count
18690
as on Dec 31, 2024
-
Investments & Acquisitions
Capsugel
& 10 more
-
Acquired by
SBI Mutual Fund
(Feb 15, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lonza
Lonza is a publicly listed company on the SIX with ticker symbol LONN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lonza
Lonza offers a comprehensive portfolio of products and services, including Integrated Biologics, Advanced Synthesis, and Specialized Modalities. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
End-to-end development and manufacturing for biologics
Services for small molecules and highly potent APIs
Development for cell, gene, and mRNA technologies
Unlock access to complete
Funding Insights of Lonza
Lonza has successfully raised a total of $100K across 6 strategic funding rounds. The most recent funding activity was a Seed round of $100 thousand completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Seed — $100,000
-
First Round
First Round
(09 Nov 2010)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2023 | Amount | Seed - Lonza | Valuation |
investors |
|
| May, 2022 | Amount | Post-IPO - Lonza | Valuation |
investors |
|
| Jan, 2019 | Amount | Grant - Lonza | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lonza
Lonza has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SBI Mutual Fund, European Union and ALSA Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in biotechnology companies for novel therapeutics is managed.
|
Founded Year | Domain | Location | |
|
AI startup acceleration and networking services are offered globally.
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lonza
Lonza has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include Capsugel, InterHealth Nutraceuticals and Lonza. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of cryopreserved hepatocytes for research purposes
|
2012 | ||||
|
Antibody-drug conjugate technology platform is developed for cancer therapies.
|
2010 | ||||
|
Viral vectors for gene therapy applications are manufactured.
|
2009 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Lonza
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lonza Comparisons
Competitors of Lonza
Lonza operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pharmaron, Pfizer, Boehringer Ingelheim, LabConnect and Dotmatics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drug discovery and development services for small molecules are provided.
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products for treating multiple diseases are provided.
|
|
| domain | founded_year | HQ Location |
Generic drugs and clinical research services are provided globally.
|
|
| domain | founded_year | HQ Location |
Laboratory testing, clinical trial research, and biopharma services are provided.
|
|
| domain | founded_year | HQ Location |
AI powered scientific data management and workflow automation solutions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lonza
Frequently Asked Questions about Lonza
When was Lonza founded?
Lonza was founded in 1897 and raised its 1st funding round 113 years after it was founded.
Where is Lonza located?
Lonza is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Who is the current CEO of Lonza?
Pierre Alain Ruffieux is the current CEO of Lonza.
Is Lonza a funded company?
Lonza is a funded company, having raised a total of $100K across 6 funding rounds to date. The company's 1st funding round was a Grant of $472.15K, raised on Nov 09, 2010.
How many employees does Lonza have?
As of Dec 31, 2024, the latest employee count at Lonza is 18,690.
What is the annual revenue of Lonza?
Annual revenue of Lonza is $7.25B as on Dec 31, 2024.
What does Lonza do?
Provider of CDMO services to pharma, biotech, and specialty ingredient markets. The company offers a complete range of development and manufacturing services for fine chemicals, advanced intermediates, active pharmaceutical ingredients (APIs), biologics, and functional ingredients. They claim to offer synergies between chemical synthesis and biotechnology to enable the production of tailor-made intermediates and APIs for use as pharmaceuticals, biotherapies, nutraceuticals, and cosmetics. Their proprietary platforms and development technologies such as GS Gene enable them to offer customized biological and chemical manufacturing solutions. In 2022, the company recorded annual revenues of 6.52B and a net profit of 1.27B.
Who are the top competitors of Lonza?
What products or services does Lonza offer?
Lonza offers Integrated Biologics, Advanced Synthesis, and Specialized Modalities.
Is Lonza publicly traded?
Yes, Lonza is publicly traded on SIX under the ticker symbol LONN.
How many acquisitions has Lonza made?
Lonza has made 11 acquisitions, including Capsugel, InterHealth Nutraceuticals, and Lonza.
Who are Lonza's investors?
Lonza has 5 investors. Key investors include SBI Mutual Fund, European Union, ALSA Ventures, U.S. Department of Defense, and Upekkha.
What is Lonza's ticker symbol?
The ticker symbol of Lonza is LONN on SIX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.